IP Library › Granted Patent US 12,642,967
Granted Patent B2
US 12,642,967 · App. 17/822,690 · Granted Jun 2, 2026

Modulation of brain-derived neurotrophic factor (BDNF)

Inventors: Howard J. Leonhardt (Mission Viejo, CA); Kelsie Leonhardt (Mission Viejo, CA); Sejal Chaudhari (Holladay, UT)
A61N1/36121A61N1/36171A61N1/36175
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,642,967
App. No.
17/822,690
Granted
Jun 2, 2026
Kind
B2
Abstract

Described is a low voltage, pulsed electrical stimulation device for controlling expression of Brain-Derived Neurotrophic Factor (“BDNF”), a useful protein, by tissues. Also described are methods of enhancing expression of BDNF in cells, particularly a method of stimulating the expression and/or release of BDNF in a cell having a gene encoding BDNF, wherein the method includes applying a bioelectric signal of from about 10 Hz to about 100 Hz (e.g., 5 Hz, 10 Hz, 40 Hz, 100 Hz, or 110 Hz) to the cell (e.g., directly, indirectly, or wirelessly). Applications in the treatment of Alzheimer's disease, depression, schizophrenia, and post-traumatic stress disorder are also disclosed.

Claims (15)

1 . A method of treating a subject for Alzheimer's disease, schizophrenia, post-traumatic stress disorder, addiction(s), and/or depression using a bioelectric stimulator comprising an electric signal generator and electrode(s), which electric signal generator is programmed to produce at least one bioelectric signal that stimulates target tissue comprising living cells of the subject to upregulate expression and/or release of brain-derived neurotrophic factor (BDNF) by the living cells, wherein the bioelectric signal comprises, within 15%, a bioelectric signal having a biphasic pulse at a frequency selected from the group consisting of 1 Hz, 10 Hz, 40 Hz, 80 Hz, and 100 Hz, with a pulse width of either about 300 microseconds or about 1,000 microseconds, and a current of about 2 mA as may be measured at the cellular level to stimulate target tissue comprising the living cells of the subject, the method comprising:

administering the bioelectric signal to the living cells via the electrode(s) for at least 5 minutes to about an hour, so as to upregulate the expression of BDNF by the living cells so as to treat the subject for Alzheimer's disease, schizophrenia, post-traumatic stress disorder, addiction(s), and/or depression.

2 . The method according to claim 1 , wherein the bioelectric signal has, within 15%, a biphasic pulse at a frequency selected from the group consisting of 1 Hz, 10 Hz, 40 Hz, 80 Hz, and 100 Hz, which bioelectric signal upregulates expression of BDNF by the living cells of the target tissue.

3 . The method according to claim 2 , wherein the bioelectric signal has a frequency of about 1 Hz.

4 . The method according to claim 2 , wherein the bioelectric signal has a frequency of about 40 Hz.

5 . The method according to claim 2 , wherein the bioelectric signal has a frequency of about 80 Hz.

6 . The method according to claim 2 , wherein the bioelectric signal has a frequency of about 100 Hz.

7 . The method according to claim 1 , wherein the target tissue comprises gray matter of the neocortex.

8 . The method according to claim 1 , wherein the bioelectric signal is administered for about 60 minutes.

9 . The method according to claim 1 , wherein the bioelectric signal comprises about 10 Hz and about 300 microseconds pulse width.

10 . The method according to claim 1 , wherein the upregulation of BDNF expression comprises at least a 2-fold increase in BDNF expression relative to an unstimulated control.

11 . The method according to claim 1 , wherein upregulation of BDNF is determined by analysis of mRNA expression normalized to a housekeeping gene.

12 . The method according to claim 1 , wherein the bioelectric stimulator is external to the subject.

13 . The method according to claim 1 , wherein the bioelectric signal is delivered wirelessly to the target tissue.

14 . The method according to claim 1 , further comprising administering stem cells to the subject.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 9, 2023
From: LEONHARDT, HOWARD J.; LEONHARDT, KELSIE; CHAUDHARI, SEJAL
To: LEONHARDT VENTURES LLC
Reel/Frame 062318/0587 →
Continuity (2)
Provisional Application 63237682 · Aug 27, 2021
Related Publication 20230071154A1 · Mar 9, 2023
References Cited (10)
US 8442653B2 · Gill · 2013 [cited by applicant]
US 10960206B2 · Leonhardt et al. · 2021 [cited by applicant]
US 20180064935A1 · Leonhardt · 2018 [cited by examiner]
US 20200230408A1 · Errico · 2020 [cited by examiner]
US 20200289826A1 · Leonhardt · 2020 [cited by applicant]
Feng et al. “Secretion of nerve growth factor, brain-derived neurotrophic factor, and glial cell-line derived neurotrophic factor in co-culture of four cell types in cerebrospinal fluidcontaining medium” Neural Regen Re… [cited by applicant]
Jiao et al. “Brain-derived neurotrophic factor protects against tau-related neurodegeneration of Alzheimer's disease” Transl Psychiatry. Oct. 4, 2016;6(10):e907. doi: 0.1038/tp.2016.186. PMID: 27701410; PMCID: PMC531554… [cited by applicant]
Sato et al. “White matter activated glial cells produce BDNF in a stroke model of monkeys.” Neurosci Res. Sep. 2009;65(1):71-8. doi: 10.1016/j.neures.2009.05.010. Epub Jun. 6, 2009. PMID: 19501123. [cited by applicant]
Wu et al. “Serum Levels of FGF21, β-Klotho, and BDNF in Stable Coronary Artery Disease Patients with Depressive Symptoms: A Cross-Sectional Single-Center Study” Front. Psychiatry, Jan. 21, 2021; https://doi.org/10.3389/… [cited by applicant]
Xiong et al. “Neurotrophins induce BDNF expression through the glutamate receptor pathway in neocortical neurons” Neuropharmacology. Jun. 2002; 42(7): 903-912. [cited by applicant]